Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization
Launched by UNIVERSIDAD PÚBLICA DE NAVARRA · Oct 29, 2023
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risk of developing blood clots in patients who are hospitalized due to acute medical conditions. The researchers want to understand whether patients receiving care at home have the same risk of blood clots as those in traditional hospital settings. To do this, they will use specific scoring systems to assess the risk and also track how much patients move around during their hospital stay, as being inactive can increase the chance of blood clots.
Eligible participants are adults aged 18 and older who are admitted with acute medical diseases, either to a conventional hospital or to a home hospital setup. Those who are near the end of life, have certain serious health conditions, or are pregnant/breastfeeding cannot participate. If you join the study, you’ll be monitored over 90 days to see if you develop any blood clots, and your activity levels will be measured using a device that tracks movement. This research aims to improve understanding of thromboembolic risks and help ensure that all patients receive the best preventive care, no matter where they are receiving treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Patients admitted with acute medical diseases to either a conventional hospitalization unit or at home hospitalization units
- • Capable and willing to provide an informed consent
- Exclusion Criteria:
- • End of life disease, palliative care or with an expected survival inferior to 3 months
- • Patients receiving therapeutic doses of any anticoagulant drug
- • Active diagnosis of thromboembolic disease
- • Prior diagnosis of atrial fibrillation
- • Pregnancy or breast-feeding.
- • SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen \<90 days before randomization.
About Universidad Pública De Navarra
The Universidad Pública de Navarra (UPNA) is a prestigious public institution committed to advancing research and education in various fields, including health sciences. As a clinical trial sponsor, UPNA leverages its academic expertise and state-of-the-art facilities to facilitate innovative research initiatives aimed at improving patient outcomes and enhancing medical knowledge. The university fosters collaboration among multidisciplinary teams, ensuring rigorous adherence to ethical standards and regulatory requirements while promoting scientific excellence. Through its clinical trials, UPNA contributes significantly to the advancement of healthcare practices and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pamplona, Navarra, Spain
Patients applied
Trial Officials
Joao Modesto dos Santos, Medical Doctor
Principal Investigator
Hospital Universitario de Navarra, Spain
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported